Table 1.
Proportion of embryos exhibiting cell-poor rifts in the stratum pyramidale of the regio superior
| Treatment | Stage of injection | Proportion of embryos exhibiting rifts |
|---|---|---|
| CR-50 ascites | E12 and E14 | 11/18 (61%) |
| CR-50 ascites | E12 and E15 | 5/7 (71%) |
| CR-50 ascites | E13 and E15 | 17/27 (63%) |
| Purified CR-50 | E12 and E14 | 4/5 (80%) |
| Purified CR-50 | E13 and E15 | 15/20 (75%) |
| CR-50 Fab | E13 and E15 | 10/16 (63%) |
| Control mouse IgG | E12 and E14 | 0/6 |
| Control mouse IgG | E12 and E15 | 0/6 |
| Control mouse IgG | E13 and E15 | 0/5 |
| Anti-fibronectin | E13 and E15 | 0/9 |
Embryos were injected at various embryonic stages with CR-50 ascites fluid, purified CR-50, Fab fragments of CR-50, control mouse IgG, or mouse anti-fibronectin mAb, and fixed at P0-P1. Because definite estimation of the cell alignment was difficult, only those exhibiting cell-poor rifts in the regio superior were counted as positive in these experiments.